StockData
Retension Pharmaceuticals, Inc. logo

Retension Pharmaceuticals, Inc. (RTSN) company profile

RTSNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 18, 2026
$13.89+2.48 (+21.74%)

Close on Nov 18, 2026Market cap $11.22MP/E –Yield –

About Retension Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

Retension Pharmaceuticals, Inc. is listed on Nasdaq under the ticker RTSN, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.

Company profile

Company

Legal name
Retension Pharmaceuticals, Inc.
Headquarters
Mclean, VA
Address
C/O Redux Therapeutics, Llc, 902 Turkey Run Road 22101
Phone
(703) 624-2024
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31

Stock & identifiers

Ticker
RTSN
Exchange
Nasdaq
IPO date
Oct 9, 2026
Filer category
<br>Emerging growth company
SEC CIK
2002988
CUSIP
76135H100
ISIN
US76135H1005
FIGI
BBG01PDS76B4
Share class FIGI
BBG01PDS76H8
LEI
529900QBUEUWO67CZD11
EIN
93-2592788

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Eric L. KellerCHIEF EXECUTIVE OFFICER, Director464,407
Robert WongVP, Chief Accounting Officer–
Sabine BissonCHIEF OPERATING OFFICER4,115
Paul SweetnamCHIEF SCIENTIFIC OFFICER409,243
Alison D. SchecterChief Medical Officer–
Alexander Duke SchwartzChief Financial Officer–
Michael J. BerendtDirector6,666
Franklin M. BergerDirector22,517
Donald OldsDirector5,637
Pavan CheruvuDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 9, 2026
Offer price
$12.00
Securities offered
3,750,000
Gross proceeds
$45.00M
Exchange
Nasdaq
First trading day
Oct 9, 2026
First-day close
$10.53-12.3%
Lock-up ends (est.)
Apr 7, 2027

“_____________________ Per Share Total Initial public offering price $ 12.00 $ 45,000,000 Underwriting discounts and commissions (1) $ 0.84 $ 3,150,000 Proceeds to us, before expenses $ 11.16 $ 41,850,000 ____________ (1) We have agreed to reimburse the underwriters for certain expenses.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?